← Back to all signals
RESEARCH PAPER ANALYSIS

Assessing the Impact of Rituximab on Treatment Outcomes in Pediatric Advanced Mature B-Non Hodgkin Lymphoma.

AI interpretation is pending for this paper.

Open original publication →
PMID41775949
JournalIndian journal of pediatrics
Publication Date2026-03-04
Ingested2026-08-02 12:06 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

OBJECTIVES: To assess the impact of adding rituximab on outcomes in children with aggressive mature B-non Hodgkin’s lymphoma (B-NHL) in resource-challenged settings. METHODS: This retrospective study was conducted at a tertiary care cancer center in India. Children aged < 18 y with newly diagnosed advanced mature B-NHL between January 2004-June 2023 were included. Patients treated in December 2016 or after were included in the post-rituximab group and those treated prior were included in the pre-rituximab group. Clinical details were compiled from hospital records. Patients in the pre- and post-rituximab groups were matched using 1:1 propensity score matching to minimize baseline differences. The impact of rituximab on event-free survival (EFS) and overall survival (OS) was examined using multivariable Cox proportional hazards regression on the matched cohort. RESULTS: The cohort included 138 patients in the pre-rituximab and 82 in the post-rituximab groups of median age eight years. The 5-year EFS was 56.7% and 69.6% in the pre- and post-rituximab groups respectively and treatment-related mortality was similar in both groups (17.4% and 17.3% respectively; p = 0.952). Rituximab use predicted for superior EFS (aHR = 0.30; 95% CI: 0.14–0.67; p = 0.003) and OS (aHR = 0.29; 95% CI = 0.12–0.70; p = 0.006) following adjustment for baseline characteristics. In a 1:1 propensity score-matched cohort, patients in the post-rituximab group had superior 5-year EFS (HR = 0.20, p = 0.0014) and OS (HR = 0.27, p = 0.016). CONCLUSIONS: The present data suggests that rituximab addition improves survival in children with aggressive advanced mature B-NHL, even in low-middle income country (LMIC) settings without an increase in treatment-related mortality.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Common Symptom with Rare Entity. Kathmandu University medical journal (KUMJ) 56.4 2 Burden and Projections of Premenopausal and Postmenopausal Breast Cancer Worldwide: A Comprehensive Analysis of GLOBOCAN 2022 Data. The breast journal 40.9 3 Characterizing Pain, Fatigue and Distress Symptom Severity and Classes in Symptomatic Early-Onset Colorectal Cancer Patients. Cancer control : journal of the Moffitt Cancer Center 82.4 4 Bloodstream infection by Fusarium Solani Complex in a paediatric patient affected by acute lymphoblastic leukaemia and P450 cytochrome polymorphism: A case report. Current medical mycology 56.3 5 Improved detection of low-level GNAQ mosaicism in Sturge-Weber syndrome through affected tissue testing, deep sequencing, and HRM-qPCR. Orphanet journal of rare diseases 54.0 6 Validation study of the Korean version of the parent protection scale. Journal of patient-reported outcomes 59.5 7 Knowledge, attitude, and practice regarding testicular cancer and testicular self-examination among medical students in Afghanistan. BMC cancer 63.4 8 Preferences, experiences and needs of parents and adolescents regarding germline sequencing in pediatric oncology. BMC pediatrics 62.5 9 Synchronous B-lymphoblastic leukemia/lymphoma and subcutaneous panniculitis-like T-cell lymphoma in an 11-year-old pediatric patient. BMC pediatrics 56.4 10 Right atrial tumour thrombus in hepatocellular carcinoma: a case report and literature review of anticoagulation dilemmas. BMC gastroenterology 49.1 11 More high-risk patients but stable levels of healthcare-associated infections and antibiotic use: findings from national point prevalence survey conducted in 2017 and 2022 in the Paris region hospitals. Antimicrobial resistance and infection control 64.9 12 Serum decoy receptor 3 (DcR3) concentrations and associations with clinical parameters in Plasmodium vivax and Plasmodium falciparum malaria. Malaria journal 71.4 13 Advanced lung cancer inflammation index predicts in-hospital mortality and refines risk stratification in patients with cirrhosis. BMC gastroenterology 72.0 14 How is the relationship between life style and cardiovascular diseases? A case- control study. BMC public health 70.0 15 Trajectory clustering of longitudinal donor chimerism after pediatric hematopoietic stem cell transplantation for non-malignant disorders. Cytotherapy 62.0 16 The impact of replacing dairy products with plant-based dairy alternatives on iodine and other micronutrients: a modelling study and evaluation of policy options to support population intake. The Lancet. Planetary health 57.5 17 CLINICAL AND CULTURAL PERSPECTIVES ON POLYCYSTIC OVARY SYNDROME IN WOMEN BASED ON SYMPTOM CLUSTERING AND DIAGNOSTIC TRENDS. Georgian medical news 61.4 18 [Thoracic pain in an adolescent with a large intrathoracic mass]. Praxis 57.5 19 Usability Testing to Improve the User Experience of an Electronic Patient-Reported Outcome System for Chimeric Antigen Receptor T-Cell Therapies. JCO clinical cancer informatics 65.1 20 The 2025 KSPNO Guideline for the Diagnosis and Treatment of Medulloblastoma. Brain tumor research and treatment 63.64 21 Diffuse Leptomeningeal Glioneuronal Tumor With Peritoneal Seeding After Ventriculoperitoneal Shunt in an Adult Patient: A Case Report. Brain tumor research and treatment 54.3 22 [Financial Toxicity in Cancer Care-2026 Update]. Gan to kagaku ryoho. Cancer & chemotherapy 75.42 23 Burden of sarcopenia and impact of structured physical programme in children with acute lymphoblastic leukaemia. Chinese clinical oncology 64.6 24 Spinal Cord Compression Syndrome Revealing Thoracic Ewing Sarcoma in a Young Adult: A Case Report. Cureus 45.5 25 Acute Incarceration of Solitary Rectal Ulcer Syndrome as an Anorectal Emergency in an Adolescent Patient: A Case Report With Long-Term Follow-Up and a Review of the Literature. Cureus 53.5 26 Case Report: Neurosurgery, octreotide, cabergoline, radiotherapy, pasireotide and pegvisomant - a multimodal strategy for adolescent acrogigantism. Frontiers in endocrinology 55.84 27 The relationship of homocysteine and its redox forms with renal toxicity after high-dose methotrexate treatment in patients with leukemia or lymphoma. Frontiers in pharmacology 72.38 28 A systematic review on the possible role of microRNA-155 in cancer treatment. Frontiers in pharmacology 75.74 29 Diagnostic delay as a prognostic factor for non-response to treatment and relapse in Mexican pediatric patients with central nervous system tumors. Frontiers in pediatrics 67.98 30 Beyond disease counts: multimorbidity patterns and self-rated health in South African adults-a network analysis of the 2016 demographic and health survey. Frontiers in public health 60.0 31 Deficiency of adenosine deaminase 2 in paediatric patients: a case series from Ireland. Frontiers in pediatrics 61.8 32 Parents' perception of enhanced oncofertility care in childhood cancer patients following routine fertility informing. Frontiers in pediatrics 61.1
PATIENT-FRIENDLY SUMMARY

Assessing the Impact of Rituximab on Treatment Outcomes in Pediatric Advanced Mature B-Non Hodgkin Lymphoma.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic